Form 8-K

8-K — Celularity Inc

Accession: 0001493152-26-044917

Filed: 2026-09-29

Period: 2026-09-29

CIK: 0001752828

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001752828

2026-09-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 29, 2026

Celularity

Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38914

83-1702591

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

170

Park Ave

Florham

Park, New Jersey

07932

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (908) 768-2170

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instructions A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Class

A Common Stock, $0.0001 par value per share

CELU

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

September 29, 2026, the Board of Directors (the “Board”) of Celularity Inc. (the “Company”) appointed Naveen

Jain to serve as a member of the Board, with his term to commence upon the expiration of the applicable waiting period following the

filing and mailing of an Information Statement pursuant to Section 14(f) of the Securities Exchange Act of 1934, as amended, and Rule

14f-1 promulgated thereunder (the “Effective Time”). Mr. Jain was designated for appointment to the Board pursuant to the

board designation rights granted to certain investors in connection with the Company’s previously announced September 2026 financing.

The financing and related board designation rights were previously disclosed by the Company in its Current Report on Form 8-K filed with

the Securities and Exchange Commission on September 28, 2026.

Mr.

Jain is the founder and Chief Executive Officer of Viome Life Sciences Inc., a health technology company that applies artificial intelligence

and molecular data to personalized health and nutrition. Mr. Jain previously founded InfoSpace, Intelius and TalentWise and is the founder

of Moon Express. His experience spans technology, health and entrepreneurship.

There

are no family relationships between Mr. Jain and any director or executive officer of the Company. Except for the board designation rights

described above, there are no arrangements or understandings between Mr. Jain and any other person pursuant to which he was selected

as a director of the Company. Mr. Jain is not a party to any transaction with the Company that would require disclosure pursuant to Item

404(a) of Regulation S-K.

Mr.

Jain will participate in the Company’s standard compensation arrangements for non-employee directors and is expected to enter into

the Company’s standard form of indemnification agreement for directors and officers. Mr. Jain has not initially been appointed

to any committee of the Board.

relation to this appointment, Diane Parks notified the Company of her decision to resign from the Board, effective as of the Effective

Time. Ms. Parks’ decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s

operations, policies or practices.

September 29, 2026, the Company issued a press release announcing Mr. Jain’s appointment to the Board. A copy of the press release

is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

99.1

Press release issued by Celularity Inc. on September 29, 2026.

104

Cover

Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

CELULARITY

INC.

Dated:

September 29, 2026

By:

/s/

K. Harold Fletcher

Name:

Harold Fletcher

Title:

Chief

Legal and Strategy Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

Celularity

Announces Naveen Jain to Join Board of Directors

Viome

founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health

FLORHAM

PARK, N.J., Sept. 29, 2026 (GLOBENEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”),

a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”),

will join its Board of Directors.

Jain

founded InfoSpace, Intelius, TalentWise and Moon Express and is the founder and CEO of Viome, which applies AI and molecular data to

personalized health and nutrition. He joins Celularity’s Board with a consumer-focused perspective on healthcare’s shift

from treating illness to helping people take a more proactive role in their health. He will bring that perspective to the challenge of

bringing promising regenerative therapies to more consumers.

“Naveen

has devoted considerable energy to the pursuit of longer, healthier lives, and shares our belief in the significant potential of regenerative

longevity,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “He has a track record

of pursuing ambitious ideas and building businesses around emerging technologies. That perspective will be valuable as we work to expand

the commercial reach of Celularity’s products and capabilities and explore the broader opportunities at the intersection of regenerative

medicine and longevity.”

“Healthcare

is shifting from treating illness after symptoms appear to helping people take a more proactive role in their health. Regenerative medicine

has the potential to be an important part of that shift. I’m joining Celularity’s Board to help translate that potential

into real-world impact, bringing a consumer perspective, commercial discipline and partnerships to the work of bringing these therapies

to more people,” said Naveen Jain.

“Naveen

brings a perspective that is crucial to what we are building around the boardroom,” said fellow Board member, Philip A. Barach.

“We have made meaningful progress strengthening Celularity’s capital structure and operating profile. The opportunity now

is to pair that discipline with an ambitious commercial vision for the assets the Company has already created.”

Mr.

Jain joins the Company’s newly constituted Board consisting of Dr. Hariri, Peter H. Diamandis, M.D., and Mr. Barach, who recently

joined the Board as part of Celularity’s broader recapitalization and strategic repositioning. Celularity expects to announce a

fifth director shortly. Mr. Jain’s appointment to the Board will become effective following completion of the applicable Rule 14f-1

information statement process.

About

Naveen Jain

From

personalized health to space exploration, Naveen Jain has built companies around questions with world-scale stakes. He is the founder

and CEO of Viome Life Sciences, where AI and molecular data are applied to personalized health and nutrition. He previously founded InfoSpace,

Intelius and TalentWise, and also founded Moon Express. Across technology, health and space, Jain has pursued a singular entrepreneurial

vision: turn emerging technologies into new ways to address humanity’s biggest challenges.

About

Celularity

Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous

cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties

and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Its cellular

therapy portfolio includes cenplacel-L, its investigational placenta-derived allogeneic cell therapy, and other investigational cellular

therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built cGMP research and manufacturing

facility supporting the development and manufacture of cellular therapies, advanced biomaterials and other longevity and wellness-focused

products.

For

more information, please visit www.celularity.com.

Forward

Looking Statements

This

press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding Mr.

Jain’s anticipated appointment to and contributions as a member of the Company’s Board of Directors; the Company’s

strategy to expand the commercial reach of its products and capabilities; the potential for regenerative medicine and the Company’s

technologies to address aging and age-related disease and contribute to more proactive approaches to health; the Company’s ability

to translate its technologies into commercial opportunities, expand access to its products and develop strategic partnerships; and the

expected appointment of an additional director.

These

forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties

that could cause actual results to differ materially, including risks relating to regulatory requirements and approvals, clinical development,

manufacturing, commercialization and market acceptance, the Company’s ability to execute its business strategy and obtain sufficient

financing, and the other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press

release. Celularity undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Investor

and Media Contact:

info@celularity.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Sep. 29, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 29, 2026

Entity File Number

001-38914

Entity Registrant Name

Celularity

Inc.

Entity Central Index Key

0001752828

Entity Tax Identification Number

83-1702591

Entity Incorporation, State or Country Code

Entity Address, Address Line One

170

Park Ave

Entity Address, City or Town

Florham

Park

Entity Address, State or Province

Entity Address, Postal Zip Code

07932

City Area Code

(908)

Local Phone Number

768-2170

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class

A Common Stock, $0.0001 par value per share

Trading Symbol

CELU

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration